Humacyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.48 USD | +16.60% | +20.70% | +92.96% |
05-10 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
03-28 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.96% | 560M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023